• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2012 Product Image

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2012

  • ID: 2366255
  • December 2012
  • 46 pages
  • Global Markets Direct

Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy. Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Chemotherapy Induced Peripheral Neuropathy Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Chemotherapy Induced Peripheral Neuropathy 7
Chemotherapy Induced Peripheral Neuropathy Therapeutics under Development by Companies 9
Chemotherapy Induced Peripheral Neuropathy Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Products under Development by Companies 15
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Products under Investigation by Universities/Institutes 16
Companies Involved in Chemotherapy Induced Peripheral Neuropathy Therapeutics Development 17
Sigma-Tau S.p.A. 17
EpiCept Corporation 18
Spectrum Pharmaceuticals, Inc. 19
CeNeRx BioPharma, Inc. 20
Spinifex Pharmaceuticals Pty Limited 21
Chemotherapy Induced Peripheral Neuropathy – Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
AmiKet - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
leteprinim - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
levocarnitine - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
duloxetine hydrochloride - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CXB-909 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
EMA-401 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
racementhol - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
AK-295 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Drug Profile Updates 36
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Discontinued Products 39
Chemotherapy Induced Peripheral Neuropathy Therapeutics - Dormant Products 40
Chemotherapy Induced Peripheral Neuropathy – Product Development Milestones 41
Featured News & Press Releases 41
Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 41
Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 42
Mar 28, 2012: Allon Receives US Patent Covering Use Of Its Neuroprotective Technology Platform 42
Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 43
Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 46
Disclaimer 46

List of Tables
Number of Products Under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2012 7
Products under Development for Chemotherapy Induced Peripheral Neuropathy – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Sigma-Tau S.p.A., H2 2012 17
EpiCept Corporation, H2 2012 18
Spectrum Pharmaceuticals, Inc., H2 2012 19
CeNeRx BioPharma, Inc., H2 2012 20
Spinifex Pharmaceuticals Pty Limited, H2 2012 21
Assessment by Monotherapy Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Drug Profile Updates 36
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Discontinued Products 39
Chemotherapy Induced Peripheral Neuropathy Therapeutics – Dormant Products 40

List of Figures
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2012 7
Products under Development for Chemotherapy Induced Peripheral Neuropathy – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos